<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757822</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-008-08S</org_study_id>
    <secondary_id>0167_2008I</secondary_id>
    <nct_id>NCT00757822</nct_id>
  </id_info>
  <brief_title>Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients</brief_title>
  <acronym>PONV</acronym>
  <official_title>Prevention of Postoperative Nausea and Vomiting in Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare two different drug regimens (oral dronabinol versus intravenous
      ondanseteron) for the prevention of post-operative nausea and vomiting (PONV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anesthesia has become remarkably safe during the past two decades, yet postoperative nausea
      and vomiting (PONV) continues to be a vexing problem with an unacceptably high incidence.
      Multiple factors including age, gender, type of surgery and anesthetic agents, perioperative
      opioid use and duration of anesthesia have been implicated in the cause of PONV. Several new
      drugs have been introduced during the last two decades to minimize PONV; however the
      incidence still remains significantly high, ranging from 30% during the first 24
      postoperatively to 35% post discharge. Unrelenting PONV results in delayed discharge which is
      particularly significant after outpatient surgery. The proposed study will examine the
      anti-emetic properties of orally administered dronabinol given immediately prior to surgery
      with standard of care intravenous ondansetron given at the end of a surgical procedure in an
      effort to assess the need for cost effective prophylaxis of PONV.

      The chemoreceptor trigger zone (CTZ) functions as emetic chemoreceptor for the vomiting
      centers. Many antiemetic drugs acting at the level of the CTZ are responsible for vomiting in
      patients receiving chemotherapy and postoperative patients. Our regimen of oral dronabinol
      has been proven to reduce the incidence of PONV in patients receiving chemotherapy. We intend
      to prove that a regimen that has been utilized in patients receiving chemotherapeutic drugs
      will work in patients with a high risk for developing PONV following surgery. We hypothesize
      that a regimen of preoperative low dose of dronabinol is superior in efficacy to a standard
      antiemetic in preventing the incidence of PONV, and thus will not only improve patient
      satisfaction but will also reduce length of stay in patients undergoing outpatient surgery.

      Specific Objectives

        1. Reduction of postoperative and postdischarge nausea and vomiting in ambulatory surgery
           patients.

        2. Reduce rate of hospital admissions and length of inpatient stay after outpatient
           surgery.

        3. Improve patient satisfaction after outpatient surgery.

      Procedure After informed consent, surgical patients scheduled for outpatient abdominal
      surgery at the Central Arkansas Veterans Healthcare System (CAVHS) who are at high risk for
      developing PONV following their procedure will be randomized to receive either the study drug
      ( preoperative oral dronabinol-5 mg) or standard therapy ( 4 mg ondansetron intravenously at
      the end of surgery). The outcome measures will be the presence or absence of PONV, the
      severity and number of such episodes, the event count of rescue antiemetic use and patient
      satisfaction. All data will be recorded by personnel who are blinded to the drug regimen.

      Relevance:

      At CAVHS, 2/3 of our patients are scheduled for outpatient surgical procedure everyday. Our
      regimen will minimize postoperative and postdischarge nausea and vomiting, improve
      post-operative care unit (PACU) length of stay, minimize unnecessary hospital admissions,
      provide patient satisfaction and cost containment. The potential for application of this
      inexpensive intervention to other surgeries is enormous. Reducing the incidence of PONV could
      have a significant impact on patient satisfaction. The intervention is very low-risk,
      efficacious, and could substantially impact on the experience and the outcome of the Veteran
      undergoing surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Postoperative Nausea and Vomiting</measure>
    <time_frame>Post-operative Care Unit (PACU) length of stay on day of surgery (time from end of surgery to transfer to discharge unit or other hospital unit)</time_frame>
    <description>The incidence of postoperative nausea (PON) and postoperative vomiting (POV) was assessed during Post-operative Care Unit (PACU) stay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Reported Post-Operative Nausea Scores on Visual Analog Scale (VAS) Scale</measure>
    <time_frame>Post-operative Care Unit (PACU) stay from end of surgery to transfer to ambulatory unit</time_frame>
    <description>VAS Scale: 0=no nausea, 1-3=mild nausea, 4-6= moderate nausea, 7-9= severe nausea, 10=extreme nausea usually accompanied with vomiting.
VAS nausea score were obtained every 30 min from entry into post-operative care unit (PACU) for first 2 hrs. and then hourly until time of transfer out of PACU.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative Nausea and Vomiting (PONV) Incidence 24-48 Hours Post Surgery</measure>
    <time_frame>24-48 hrs post surgery</time_frame>
    <description>Participants were queried for presence of postoperative nausea (PON) or postoperative vomiting (POV) during the 24-48 hr window post surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-Operative Care Unit Length of Stay (Min)</measure>
    <time_frame>Day of surgery (time from end of surgery to transfer to ambulatory pre-discharge unit or other unit)</time_frame>
    <description>Length of time in PACU (minutes) measured from end of surgery to time of transfer to ambulatory care prior to home discharge or time to hospital admission if applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Surgery Hospital Admissions (All Cause) After Out-patient Abdominal Procedure</measure>
    <time_frame>Post-operative Day of Surgery (DOS)</time_frame>
    <description>Number of all-cause hospital admissions on day of elective out-patient surgery .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Antiemetic Use</measure>
    <time_frame>End of surgery to 48 hr post surgery</time_frame>
    <description>Percentage of participants requiring post-operative anti-emetic medications.. Anti-emetic medication need was assessed during a) post-operative care unit (PACU) stay and b)during the first 48 hrs. following discharge from PACU to home or if applicable to in-patient unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction: Willingness to Take Pre-operative Medication for Post-operative Nausea and/or Vomiting</measure>
    <time_frame>Post operative follow up interviews 24 hrs to 6 wks</time_frame>
    <description>Percent of participants who responded that they would be willing to take preemptive medication for nausea and vomiting for subsequent surgeries when queried during post-operative follow-up interviews at 24-48 hrs or 2-6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction 2: Willingness to Pay Extra Money for Post-Operative Nausea and Vomiting (PONV) Preventive Medication</measure>
    <time_frame>Post-operative follow-up interviews 24 hr to 6 weeks post surgery</time_frame>
    <description>Percent of participants willing to pay extra money for preemptive medication for PONV for subsequent surgical procedures when queried at post-operative 24-48 hr. and at 2-6 wk. follow-up interviews.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dronabinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ondansetron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Marinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients undergoing outpatient operations for intra-abdominal or abdominal wall
             procedures (e.g. hernias) under general anesthesia.

          -  Patients that are at increased risk for PONV based on the Koivuranta risk scoring
             system, with inclusion of patients having a Koivuranta risk score (K score) of 2 or
             more.

          -  Ability to give informed consent.

          -  Veteran eligible for treatment.

        Exclusion Criteria:

          -  Patients &lt;18 years old

          -  Patients with a history of hypersensitivity to cannabinoids or sesame oil --Patients
             with current substance abuse.

        Substance abuse will be identified meeting one or both of the following criteria:

          -  a) Review the participant's medical chart to identify inpatient, residential, or
             outpatient treatment for alcohol or drug dependence as recorded in the Veterans Health
             Administration Computerized Patient Record system (CPRS) within the preceding six
             months.

        OR

          -  b) Patient report. Exclude patients who report current marijuana or cocaine use within
             the past 30 days.

        If a drug screen is clinically indicated and is positive the patient will NOT be entered
        into the study.

          -  Patients taking medications known to have significant drug-drug interactions with the
             prescribed drug and study drugs, Dronabinol and Ondansetron, will be reviewed in
             Micromedex. Micromedex is a medication database used by Central Arkansas Veterans
             Healthcare System (CAVHS). If the drug could have a drug-drug interaction with either
             dronabinol or ondansetron the patients will NOT be entered into the study. If a drug
             is confirmed via Micromedex not to have a drug-drug interaction, the patient will be
             eligible for study participation.

          -  Pregnant women

          -  Patients with prolonged QTC intervals on electrocardiogram (EKG).

          -  Patients enrolled in another clinical trial at the time of randomization.

          -  Inability to adhere to study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue A Theus, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Central Arkansas Veterans Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Arkansas Veterans Healthcare System-John L McClellan Memorial Veterans Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <results_first_submitted>September 28, 2015</results_first_submitted>
  <results_first_submitted_qc>April 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2016</results_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period was from 12-02-2009 to 11-20-2013. Participants were recruited during pre-surgery or preanesthesia clinic visits for elective outpatient abdominal surgery lasting at least 1 hr. Inclusion criteria included high risk for post-operative nausea and vomiting (PONV) as measured by a Koivuranta score (K score) of 2 or more.</recruitment_details>
      <pre_assignment_details>36 participants were withdrawn prior to assignment into a treatment arm: 8 participants voluntarily withdrew prior to surgery date, 2 did not meet inclusion criteria, 6 had exclusion criteria, 3 withdrawn when study was closed to enrollment, 17 were withdrawn due to cancellation or re-scheduled surgery incompatible with study schedules.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Dronabinol</title>
          <description>dronabinol
Dronabinol: Dronabinol (5mg) will be administered po 30-60 min prior start of surgery.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Ondansetron</title>
          <description>ondansetron
Ondansetron: Ondansetron (4 mg) will be administered iv 20-30 min prior to end of surgery in those patients not receiving Dronabinol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day of Surgery (DOS) Assessment</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrawal by Subject-no Intervention</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>DOS Withdrawn by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="6">No longer met inclusion criteria or developed exclusion criteria on DOS</participants>
                <participants group_id="P2" count="11">No longer met inclusion criteria or developed exclusion criteria on DOS</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Intervention</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>DOS: Post-operative Assessments</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>24-48 hr Telephone Assessment</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2-6 wk Post-op Assessment</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Data Entry, QC Assessment</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrawn-low-risk for PONV</title>
              <participants_list>
                <participants group_id="P1" count="12">K score for PONV risk&lt;2</participants>
                <participants group_id="P2" count="9">K score for PONV risk &lt; 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrawn-protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Data Lock, Unblinding Analysis</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Dronabinol</title>
          <description>dronabinol
Dronabinol: Dronabinol (5mg) will be administered po 20-60 min pre-operatively.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Ondansetron</title>
          <description>ondansetron
Ondansetron: Ondansetron (4mg) will be administered iv intraoperatively in those patients not receiving Dronabinol.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="12.5"/>
                    <measurement group_id="B2" value="57.6" spread="13.2"/>
                    <measurement group_id="B3" value="57.7" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Risk scores for PONV</title>
          <description>Post-operative Nausea and Vomiting (PONV) risk score is defined as by adding risk factors on the Koivuranta scale ( e.g. where each of the following factors: surgery lasting more than 60 minutes, female, non-smoking status, history of PONV, and history of motion sickness is assigned a value of one if present and the risk score is the summation of each factor). A K score of 0-1 represents low risk for PONV. The risk increases with K scores of 2 or more, 5 being the maximum.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>K score=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K score &gt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Postoperative Nausea and Vomiting</title>
        <description>The incidence of postoperative nausea (PON) and postoperative vomiting (POV) was assessed during Post-operative Care Unit (PACU) stay.</description>
        <time_frame>Post-operative Care Unit (PACU) length of stay on day of surgery (time from end of surgery to transfer to discharge unit or other hospital unit)</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1:Dronabinol</title>
            <description>dronabinol
Dronabinol: Dronabinol (5mg) will be administered po 20-60 min pre-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2:Ondansetron</title>
            <description>ondansetron
Ondansetron: Ondansetron (4mg) will be administered iv intraoperatively in those patients not receiving Dronabinol.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Postoperative Nausea and Vomiting</title>
          <description>The incidence of postoperative nausea (PON) and postoperative vomiting (POV) was assessed during Post-operative Care Unit (PACU) stay.</description>
          <population>Per protocol</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Incidence PACU PON</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence PACU POV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The incidence of PON per arm will be determined and expressed as a percentage of the total patients per arm. Treatment efficacy will be measured as the percentage-point decrease in PON in the treatment arm (Marinol) compared to the standard therapy arm (ondansetron). Null hypothesis: Marinol treatment is not superior to ondansetron treatment. We will test the statistical significance with Fisher's Exact test at a significance level of 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.76</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>4.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>18.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Reported Post-Operative Nausea Scores on Visual Analog Scale (VAS) Scale</title>
        <description>VAS Scale: 0=no nausea, 1-3=mild nausea, 4-6= moderate nausea, 7-9= severe nausea, 10=extreme nausea usually accompanied with vomiting.
VAS nausea score were obtained every 30 min from entry into post-operative care unit (PACU) for first 2 hrs. and then hourly until time of transfer out of PACU.</description>
        <time_frame>Post-operative Care Unit (PACU) stay from end of surgery to transfer to ambulatory unit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Dronabinol</title>
            <description>dronabinol
Dronabinol: Dronabinol (5mg) will be administered po 20-60 min pre-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2:Ondansetron</title>
            <description>ondansetron
Ondansetron: Ondansetron (4mg) will be administered iv intraoperatively in those patients not receiving Dronabinol.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Reported Post-Operative Nausea Scores on Visual Analog Scale (VAS) Scale</title>
          <description>VAS Scale: 0=no nausea, 1-3=mild nausea, 4-6= moderate nausea, 7-9= severe nausea, 10=extreme nausea usually accompanied with vomiting.
VAS nausea score were obtained every 30 min from entry into post-operative care unit (PACU) for first 2 hrs. and then hourly until time of transfer out of PACU.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No nausea (VAS score=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4"/>
                    <measurement group_id="O2" value="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Nausea (VAS score=1-3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Nausea (VAS score =4-6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe nausea (VAS score=7-9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme nausea (VAS score=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.92</p_value>
            <method>Fisher Exact</method>
            <method_desc>One-sided Fisher's Exact test was performed comparing the percentage of subjects with at least one VAS score &gt; 0. (Marinol&gt;Ondansetron).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Nausea and Vomiting (PONV) Incidence 24-48 Hours Post Surgery</title>
        <description>Participants were queried for presence of postoperative nausea (PON) or postoperative vomiting (POV) during the 24-48 hr window post surgery.</description>
        <time_frame>24-48 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Dronabinol</title>
            <description>dronabinol
Dronabinol: Dronabinol (5mg) will be administered po 20-60 min pre-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2:Ondansetron</title>
            <description>ondansetron
Ondansetron: Ondansetron (4mg) will be administered iv intraoperatively in those patients not receiving Dronabinol.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Nausea and Vomiting (PONV) Incidence 24-48 Hours Post Surgery</title>
          <description>Participants were queried for presence of postoperative nausea (PON) or postoperative vomiting (POV) during the 24-48 hr window post surgery.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24-48hr PON incidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4"/>
                    <measurement group_id="O2" value="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-48 hr POV incidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.55</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>7.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Operative Care Unit Length of Stay (Min)</title>
        <description>Length of time in PACU (minutes) measured from end of surgery to time of transfer to ambulatory care prior to home discharge or time to hospital admission if applicable.</description>
        <time_frame>Day of surgery (time from end of surgery to transfer to ambulatory pre-discharge unit or other unit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1:Dronabinol</title>
            <description>dronabinol
Dronabinol: Dronabinol (5mg) will be administered po 20-60 min pre-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2:Ondansetron</title>
            <description>ondansetron
Ondansetron: Ondansetron (4mg) will be administered iv intraoperatively in those patients not receiving Dronabinol.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Operative Care Unit Length of Stay (Min)</title>
          <description>Length of time in PACU (minutes) measured from end of surgery to time of transfer to ambulatory care prior to home discharge or time to hospital admission if applicable.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="73" upper_limit="139"/>
                    <measurement group_id="O2" value="97.0" lower_limit="70" upper_limit="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.981</p_value>
            <method>Wilcoxon Rank-Sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Surgery Hospital Admissions (All Cause) After Out-patient Abdominal Procedure</title>
        <description>Number of all-cause hospital admissions on day of elective out-patient surgery .</description>
        <time_frame>Post-operative Day of Surgery (DOS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1:Dronabinol</title>
            <description>dronabinol
Dronabinol: Dronabinol (5mg) will be administered po 20-60 min pre-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Ondnasetron</title>
            <description>ondansetron
Ondansetron: Ondansetron (4mg) will be administered iv intraoperatively in those patients not receiving Dronabinol.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Surgery Hospital Admissions (All Cause) After Out-patient Abdominal Procedure</title>
          <description>Number of all-cause hospital admissions on day of elective out-patient surgery .</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DOS admission-observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DOS admission- urinary retension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DOS admission-pain management</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DOS admission- low SpO2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DOS admission -intractable nausea/vomitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.90</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Antiemetic Use</title>
        <description>Percentage of participants requiring post-operative anti-emetic medications.. Anti-emetic medication need was assessed during a) post-operative care unit (PACU) stay and b)during the first 48 hrs. following discharge from PACU to home or if applicable to in-patient unit.</description>
        <time_frame>End of surgery to 48 hr post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1:Dronabinol</title>
            <description>dronabinol
Dronabinol: Dronabinol (5mg) will be administered po 20-60 min pre-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Ondansetron</title>
            <description>ondansetron
Ondansetron: Ondansetron (4mg) will be administered iv intraoperatively in those patients not receiving Dronabinol.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Antiemetic Use</title>
          <description>Percentage of participants requiring post-operative anti-emetic medications.. Anti-emetic medication need was assessed during a) post-operative care unit (PACU) stay and b)during the first 48 hrs. following discharge from PACU to home or if applicable to in-patient unit.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medication need during PACU stay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication need for first 48 hrs after discharge t</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.37</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction: Willingness to Take Pre-operative Medication for Post-operative Nausea and/or Vomiting</title>
        <description>Percent of participants who responded that they would be willing to take preemptive medication for nausea and vomiting for subsequent surgeries when queried during post-operative follow-up interviews at 24-48 hrs or 2-6 weeks.</description>
        <time_frame>Post operative follow up interviews 24 hrs to 6 wks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1:Dronabinol</title>
            <description>dronabinol
Dronabinol: Dronabinol (5mg) will be administered po 20-60 min pre-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2:Ondansetron</title>
            <description>ondansetron
Ondansetron: Ondansetron (4mg) will be administered iv intraoperatively in those patients not receiving Dronabinol.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction: Willingness to Take Pre-operative Medication for Post-operative Nausea and/or Vomiting</title>
          <description>Percent of participants who responded that they would be willing to take preemptive medication for nausea and vomiting for subsequent surgeries when queried during post-operative follow-up interviews at 24-48 hrs or 2-6 weeks.</description>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24-48 hr post-operative interview</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-6 week post-operative interview</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparisons at 24-48 hr post-surgery. Null hypothesis: dronabinol is not superior to ondansetron in patient satisfaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.75</p_value>
            <method>FREQ Procedure</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparisons of both arms at 2-6 weeks; null hypothesis: dronabinol is not superior to ondansetron in patient satisfaction</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.10</p_value>
            <method>FREQ procedure</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction 2: Willingness to Pay Extra Money for Post-Operative Nausea and Vomiting (PONV) Preventive Medication</title>
        <description>Percent of participants willing to pay extra money for preemptive medication for PONV for subsequent surgical procedures when queried at post-operative 24-48 hr. and at 2-6 wk. follow-up interviews.</description>
        <time_frame>Post-operative follow-up interviews 24 hr to 6 weeks post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1:Dronabinol</title>
            <description>dronabinol
Dronabinol: Dronabinol (5mg) will be administered po 20-60 min pre-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2:Ondansetron</title>
            <description>ondansetron
Ondansetron: Ondansetron (4mg) will be administered iv intraoperatively in those patients not receiving Dronabinol.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction 2: Willingness to Pay Extra Money for Post-Operative Nausea and Vomiting (PONV) Preventive Medication</title>
          <description>Percent of participants willing to pay extra money for preemptive medication for PONV for subsequent surgical procedures when queried at post-operative 24-48 hr. and at 2-6 wk. follow-up interviews.</description>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24-48 hr. post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-6 wk post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of both group responses at 24-48 hours.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.29</p_value>
            <method>FREQ procedure</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparisons of both arms at 2-6 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.55</p_value>
            <method>FREQ Procedure</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1-72 days post-surgery (e.g. 30 days post last follow-up visit at 2-6 weeks)</time_frame>
      <desc>Participant medical chart review at 2-6 weeks post operation follow-up assessment and at weekly intervals up to 30 days after last follow-up/end of participation in study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dronabinol- Experimental Therapy</title>
          <description>Dronabinol (5mg) was administered po 30-60 min prior to start of elective abdominal surgery scheduled for same day discharge to home.</description>
        </group>
        <group group_id="E2">
          <title>Ondansetron-control Therapy</title>
          <description>Ondansetron (4 mg) was administered iv 20-30 min prior to end of elective abdominal surgery scheduled for same day discharge to home.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hospitilization due to co-morbid preexisting conditions</sub_title>
                <description>iatrogenic bradycardia/hypotension</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization due to co-morbid preexisting conditions</sub_title>
                <description>Participant re-hospitalized within 30 days of study follow-up for further GI work-up due to pre-existing conditions.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>post-operative overnight hospitalization secondary to low sPO2</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>overnight hospitalization secondary to unanticipated extensive surgery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>overnight hospitalization secondary to urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>overnight hospitalization secondary to excessive postoperative pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>post-operative complication due to surgery</sub_title>
                <description>Patient presented and re-hospitalized due to issues secondary to surgical procedure following discharge (e.g. infection, excessive swelling, suture rupture)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Swelling at incision site</sub_title>
                <description>AE was noted if participant complained of or was seen for any swelling, redness, or other issues involving incision site and wound healing</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Muhammad Jaffar</name_or_title>
      <organization>Central Arkansas Veterans Healthcare System</organization>
      <phone>501-688-9310</phone>
      <email>Muhammad.Jaffar@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

